SEARCH

SEARCH BY CITATION

References

  • Baichwal, V.R. & Sugden, B. (1987) Posttranslational processing of an Epstein-Barr virus-encoded membrane protein expressed in cells transformed by Epstein-Barr virus. Journal of Virology, 61, 866875.
  • Berger, C., McQuain, C., Sullivan, J.L., Nadal, D., Quesenberry, P.J., Knecht, H. (1997) The 30-bp deletion variant of Epstein-Barr virus-encoded latent membrane protein-1 prevails in acute infectious mononucleosis. Journal of Infectious Diseases, 176, 13701373.
  • Brodeur, S.R., Cheng, G., Baltimore, D., Thorley-Lawson, D.A. (1997) Localization of the major NF-kappaB-activating site and the sole TRAF3 binding site of LMP-1 defines two distinct signaling motifs. Journal of Biological Chemistry, 272, 1977719784.DOI: 10.1074/jbc.272.32.19777
  • Chiang, A.K., Tao, Q., Srivastava, G., Ho, F.C. (1996) Nasal NK- and T-cell lymphomas share the same type of Epstein-Barr virus latency as nasopharyngeal carcinoma and Hodgkin's disease. International Journal of Cancer, 68, 285290.DOI: 10.1002/(sici)1097-0215(19961104)68:3<285::aid-ijc3>3.0.co;2-y
  • Cohen, J.I., Wang, F., Kieff, E. (1991) Epstein-Barr virus nuclear protein 2 mutations define essential domains for transformation and transactivation. Journal of Virology, 65, 25452554.
  • Cruz, I., Van Den Brule, A.J., Brink, A.A., Snijders, P.J., Walboomers, J.M., Van Der Waal, I., Meijer, C.J. (2000) No direct role for Epstein-Barr virus in oral carcinogenesis: a study at the DNA, RNA and protein levels. International Journal of Cancer, 86, 356361.DOI: 10.1002/(sici)1097-0215(20000501)86:3<356::aid-ijc9>3.3.co;2-n
  • Devergne, O., Hatzivassiliou, E., Izumi, K.M., Kaye, K.M., Kleijen, M.F., Kieff, E., Mosialos, G. (1996) Association of TRAF1, TRAF2, and TRAF3 with an Epstein-Barr virus LMP-1 domain important for B-lymphocyte transformation: role in NF-κB activation. Molecular and Cellular Biology, 16, 70987108.
  • Dirnhofer, S., Angeles-Angeles, A., Ortiz-Hidalgo, C., Reyes, E., Gredler, E., Krugmann, J., Fend, F., Quintanilla-Martinez, L. (1999) High prevalence of a 30-base pair deletion in the Epstein-Barr virus (EBV) latent membrane protein 1 gene and of strain type B EBV in Mexican classical Hodgkin's disease and reactive lymphoid tissue. Human Pathology, 30, 781787.
  • Dolcetti, R., Zancai, P., De Re, V., Gloghini, A., Bigoni, B., Pivetta, B., De Vita, S., Carbone, A., Boiocchi, M. (1997) Epstein-Barr virus strains with latent membrane protein-1 deletions: prevalence in the Italian population and high association with human immunodeficiency virus-related Hodgkin's disease. Blood, 89, 17231731.
  • Eliopoulos, A.G. & Rickinson, A.B. (1998) Epstein-Barr virus: LMP-1 masquerades as an active receptor. Current Biology, 8, 196198.
  • Eliopoulos, A.G., Blake, S.M., Floettmann, J.E., Rowe, M., Young, L.S. (1999) Epstein-Barr virus encoded latent membrane protein 1 activates the JNK pathway through its extreme C terminus via a mechanism involving TRADD and TRAF2. Journal of Virology, 73, 10231035.
  • Fennewald, S., Van Santen, V., Kieff, E. (1984) Nucleotide sequence of an mRNA transcribed in latent growth-transforming virus infection indicates that it may encode a membrane protein. Journal of Virology, 51, 411419.
  • Gires, O., Zimber-Strobl, U., Gonnella, R., Ueffing, M., Marschall, G., Zeidler, R., Pich, D., Hammerschmidt, W. (1997) Latent membrane protein 1 of Epstein-Barr virus mimics a constitutively active receptor molecule. EMBO Journal, 16, 61316140.
  • Gires, O., Kohlhuber, F., Kilger, E., Baumann, M., Kieser, A., KaiSeries, C., Zeidler, R., Scheffer, B., Ueffing, M., Hammerschmidt, W. (1999) Latent membrane protein 1 of Epstein-Barr virus interacts with JAK3 and activates STAT proteins. EMBO Journal, 18, 30643073.
  • Hamilton-Dutoit, S.J., Rea, D., Raphael, M., Sandjev, K., Delecluse, H.J., Gisselbrecht, C., Marelle, L., Van Krieken, H.J., Pallesen, G. (1993) Epstein-Barr virus-latent gene expression and tumor cell phenotype in acquired immunodeficiency syndrome-related non-Hodgkin's lymphoma. Correlation of lymphoma phenotype with three distinct patterns of viral latency. American Journal of Pathology, 143, 10721085.
  • Hammerschmidt, W. & Sugden, B. (1989) Genetic analysis of immortalizing functions of Epstein-Barr virus in human B lymphocytes. Nature, 340, 393397.
  • Henderson, S., Rowe, M., Gregory, C., Croom-Carter, D., Wang, F., Longnecker, R., Kieff, E., Rickinson, A. (1991) Induction of bcl-2 expression by Epstein-Barr virus latent membrane protein 1 protects infected B cells from programmed cell death. Cell, 65, 11071115.
  • Hennessy, K., Fennewald, S., Hummel, M., Cole, T., Kieff, E. (1984) A membrane protein encoded by Epstein-Barr virus in latent growth-transforming infection. Proceedings of the National Academy of Sciences of the United States of America, 81, 72077211.
  • Jiang, S., Munker, R., Andreeff, M. (1996) Bcl-2 is expressed in human natural killer cells and is regulated by interleukin-2. Natural Immunity, 15, 312317.
  • Kaye, K.M., Izumi, K.M., Kieff, E. (1993) Epstein-Barr virus latent membrane protein 1 is essential for B-lymphocyte growth transformation. Proceedings of the National Academy of Sciences of the United States of America, 90, 91509154.
  • Kaye, K.M., Devergne, O., Harada, J.N., Izumi, K.M., Yalamanchili, R., Kieff, E., Mosialos, G. (1996) Tumor necrosis factor receptor associated factor 2 is a mediator of NF-κB activation by latent infection membrane protein 1, the Epstein-Barr virus transforming protein. Proceedings of the National Academy of Sciences of the United States of America, 93, 1108511090.
  • Kenney, J.L., Guinness, M.E., Curiel, T., Lacy, J. (1998) Antisense to the Epstein-Barr Virus (EBV)-encoded latent membrane protein 1 (LMP-1) suppresses LMP-1 and bcl-2 expression and promotes apoptosis in EBV-immortalized B cells. Blood, 92, 17211727.
  • Kieff, E. (1996) Epstein-Barr virus and its replication. In: Fields Virology (ed. by B.N.Fields, D.M.Knipe & P.M. Howley), pp. 23432396. Lippincott-Raven, Philadelphia.
  • Kieff, E. & Liebowitz, D. (1990) Epstein-Barr virus and its replication. In: Virology (ed. by B.N.Fields, D.M.Knipe & R.M. Chanock), p. 1889. Raven, New York, NY.
  • Kieser, A., Kilger, E., Gires, O., Ueffing, M., Kolch, W., Hammerschmidt, W. (1997) Epstein-Barr virus latent membrane protein-1 triggers AP-1 activity via the C-Jun N-terminal kinase cascade. EMBO Journal, 16, 64786485.
  • Kilger, E., Kieser, A., Baumann, M., Hammerschmidt, W. (1998) Epstein-Barr virus mediated B-cell proliferation is dependent upon latent membrane protein 1, which stimulates an activated CD40 receptor. EMBO Journal, 17, 17001709.
  • Kingma, D.W., Weiss, W.B., Jaffe, E.S., Kumar, S., Frekko, K., Raffeld, M. (1996) Epstein-Barr virus latent membrane protein-1 oncogene deletions: correlations with malignancy in Epstein-Barr virus-associated lymphoproliferative disorders and malignant lymphomas. Blood, 88, 242251.
  • Liang, R., Todd, D., Chan, T.K., Chiu, E., Lie, A., Kwong, Y.L., Choy, D., Ho, F.C. (1995) Treatment outcome and prognostic factor for primary nasal lymphoma. Journal of Clinical Oncology, 13, 666670.
  • Liebowitz, D. (1994) Nasopharyngeal carcinoma: The Epstein–Barr virus association. Seminars in Oncology, 21, 376381.
  • Liebowitz, D., Wang, D., Kieff, E. (1986) Orientation and patching of the latent infection membrane protein encoded by Epstein-Barr virus. Journal of Virology, 58, 233237.
  • Mansoor, A., Stevenson, M.S., Li, R.Z., Frekko, K., Weiss, W., Ahmad, M., Khan, A.H., Mushtaq, S., Saleem, M., Raffeld, M., Kingma, D.W., Jaffe, E.S. (1997) Prevalence of Epstein-Barr viral sequences and EBV LMP-1 oncogene deletions in Burkitt's lymphoma from Pakistan: epidemiological correlations. Human Pathology, 28, 283288.
  • Middleton, T., Gahn, T.A., Martin, J.M., Sugden, B. (1991) Immortalizing genes of Epstein-Barr virus. In: Advances in Viral Research, (ed. by K.Maramorosch, F.A.Murphy & J.A. Shatkin), pp. 1955. Academic, San Diego, CA.
  • Miller, C.L., Burkhardt, A.L., Lee, J.H., Stealey, B., Longnecker, R., Bolen, J.B., Kieff, E. (1995) Integral membrane protein 2 of Epstein-Barr virus regulates reactivation from latency through dominant negative effects on protein-tyrosine kinases. Immunity, 2, 155166.
  • Miller, W.E., Mosialos, G., Kieff, E., Raab-Traub, N. (1997) Epstein-Barr virus LMP-1 induction of the epidermal growth factor receptor is mediated through a TRAF signaling pathway distinct from NF-κB activation. Journal of Virology, 71, 586594.
  • Mosialos, G., Birkenbach, M., Yalamanchili, R., VanArsdale, T., Ware, C., Kieff, E. (1995) The Epstein-Barr virus transforming protein LMP-1 engages signaling proteins for the tumor necrosis factor receptor family. Cell, 80, 389399.
  • Murray, P.G., Swinnen, L.J., Constandinou, C.M., Pyle, J.M., Carr, T.J., Hardwick, J.M., Ambinder, R.F. (1996) Bcl-2 but not its Epstein-Barr virus-encoded homologue, BHRF-1, is commonly expressed in posttransplantation lymphoproliferative disorders. Blood, 87, 706711.
  • Okan, I., Wang, Y., Chen, F., Hu, L.F., Imreh, S., Klein, G., Wiman, G. (1995) The EBV-encoded LMP-1 protein inhibits p53-triggered apoptosis but not growth arrest. Oncogene, 11, 10271031.
  • Rickinson, A.B. & Kieff, E. (1996) Epstein-Barr virus. In: Fields Virology (ed. by B.N.Fields, D.M.Knipe & P.M. Howley), pp. 23972446. Lippincott-Raven, Philadelphia.
  • Rowe, M., Peng-Pilon, M., Huen, D.S., Hardy, R., Croom-Carter, D., Lundgren, E., Rickinson, A.B. (1994) Upregulation of bcl-2 by the Epstein-Barr virus latent-membrane protein LMP-1: a B-cell-specific response that is delayed relative to NF-κB activation and to induction of cell surface markers. Journal of Virology, 68, 56025612.
  • Sandberg, M., Hammerschmidt, W., Sugden, B. (1997) Characterization of LMP−1′S association with TRAF1, TRAF2, and TRAF3. Journal of Virology, 71, 46494656.
  • Speck, S.H. & Strominger, J.L. (1989) Transcription of Epstein-Barr virus in latently infected, growth transformed lymphocytes. In: Advances in Viral Oncology, (ed. by G.Klein), pp. 133163. Raven, New York, NY.
  • Suzumiya, J., Ohshima, K., Takeshita, M., Kanda, M., Kawasaki, C., Kimura, N., Tamura, K., Kikuchi, M. (1999) Nasal lymphomas in Japan: a high prevalence of Epstein-Barr virus type A and deletion within the latent membrane protein gene. Leukemia and Lymphoma, 35, 567578.
  • Tomkinson, B., Robertson, E., Kieff, E. (1993) Epstein-Barr virus nuclear proteins EBNA-3A, and EBNA-3C are essential for B-lymphocyte growth tranformation. Journal of Virology, 67, 20142025.
  • Tsuchiyama, J., Yoshino, T., Mori, M., Kondoh, E., Oka, T., Akagi, T., Hiraki, A., Nakayama, H., Shibuya, A., Ma, Y., Kawabata, T., Okada, S., Harada, M. (1998) Characterization of a novel human natural killer-cell line (NK-YS) established from natural killer cell lymphoma/leukemia associated with Epstein-Barr Virus infection. Blood, 92, 13741383.
  • Wang, F., Gregory, C., Sample, C., Rowe, M., Liebowitz, D., Murray, R., Rickinson, A., Kieff, E. (1990) Epstein-Barr virus latent-membrane protein (LMP-1) and nuclear proteins 2 and 3C are effectors of phenotypic changes in B lymphocytes: EBNA-2 and LMP-1 cooperatively induce CD23. Journal of Virology, 64, 23092318.
  • Yoneda, N., Tatsumi, E., Kawano, S., Teshigawara, K., Oka, T., Fukuda, M., Yamaguchi, N. (1992) Detection of Epstein-Barr virus genome in natural-killer-like cell line, YT. Leukemia, 6, 136141.